New Data Show Duloxetine Maintained Pain Reduction for More Than Six Months in Patients With Diabetic Peripheral Neuropa

Duloxetine for major depressive episodes and diabetic peripheral neuropathic pain is marketed by Lilly and Boehringer Ingelheim in all countries included in the partnership under the brand name Cymbalta, except for Germany, Greece, Italy and Spain. In Germany, Lilly and Boehringer Ingelheim market duloxetine for major depressive episodes under the brand name Cymbalta, and market the product for diabetic peripheral neuropathic pain as Ariclaim(R). In Greece, Italy and Spain, Lilly markets the product as Cymbalta, and Boehringer Ingelheim markets the product as Xeristar(R). In the United States, Cymbalta is marketed by Lilly and Quintiles. In Japan, duloxetine is co-developed and co-marketed by Lilly and Shionogi & Co., Ltd.

Duloxetine for stress urinary incontinence is marketed by Lilly under the brand name Yentreve(R).

References

(1) Skljarevski, V. et al. Evaluating the Maintenance of Effect of Duloxetine in Patients with Diabetic Peripheral Neuropathic Pain. Poster presented at the Annual World Congress of Pain. 19 August 2008

(2) Skljarevski, V. et al. Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain. HMEM. Eli Lilly Research Laboratories.

(3) IDF. Diabetes Prevalence. International Diabetes Federation. Available at http://www.idf.org/home/index.cfm?node=2.... Accessed 24 June 2008.

(4) National Diabetes Information Clearinghouse, Diabetic Neuropathies: The Nerve Damage of Diabetes. National Institute of Diabetes and Digestive and Kidney Disease. Available at http://www.diabetes.niddk.nih.gov/dm/pub..., Accessed 24 June 2008.

(5) Tesfaye S. and Kempler P. Painful Diabetic Neuropathy. Diabetologia. 2005; 48: 805-807

(6) Wernicke JF, Lu Y, D'Souza DN, Waninger A, Tran PV. Duloxetine at doses of 60 mg QD and 60 mg BID is effective treatment of diabetic neuropathic pain. Paper presented at: American Academy of Neurology; April 24-May 1, 2004; San Francisco, CA.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

Sonja Popp-Stahly of Eli Lilly and Company, +1-317-655-2993; or Eva Freitag of Boehringer Ingelheim, +49-6132-77-2964 ; Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO, PRN Photo Desk, photodesk@prnewswire.com